Development of plasma cell myeloma in a B-cell chronic lymphocytic leukemia patient with chromosome 12 trisomy by unknown
Pereira et al. BMC Research Notes 2013, 6:433
http://www.biomedcentral.com/1756-0500/6/433CASE REPORT Open AccessDevelopment of plasma cell myeloma in a B-cell
chronic lymphocytic leukemia patient with
chromosome 12 trisomy
Welbert de Oliveira Pereira1,2*, Nydia Strachman Bacal2,5, Rodolfo Patussi Correia2, Ruth Hissae Kanayama2,
Elvira Deolinda Veloso3, Daniela Borri3, Nelson Hamerschlak4 and Paulo Vidal Campregher1,6Abstract
Background: Cancer development results from the progressive accumulation of genomic abnormalities that
culminate in the neoplastic phenotype. Cytogenetic alterations, mutations and rearrangements may be considered
as molecular legacy which trace the clonal history of the disease. Concomitant tumors are reported and they may
derive from a common or divergent founder clone. B-cell chronic lymphocytic leukemia (B-CLL) and plasma cell
myeloma (PCM) are both mature B-cell neoplasms, and their concomitancy, albeit rare, is documented.
Case presentation: Here, we described a patient with prior B-CLL with secondary development of PCM. Cytogenetic
and multi parametric flow cytometry analyses were performed. The B-CLL population presented chromosome 12
trisomy, unlikely the arisen PCM population.
Conclusion: The close follow up of B-CLL patients is important for early intervention in case of development of other
malignancy, such as myeloma. Our observation suggests these two diseases may have arisen from different clones. We
understand that the investigation of clonal origin may provide important information regarding therapeutic decisions,
and should be considered in concomitant neoplasm.
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It has been demonstrated that cancers are composed
of heterogeneous malignant cell populations, harboring
distinct sets of genomic aberrations such as mutations,
copy number alterations, chromosomes abnormalities etc.
[1-4]. Another phenomenon described in hematological
malignancies is lineage plasticity [5], in which two differ-
ent malignancies originate from the same malignant cell.
B-cell chronic lymphocytic leukemia (B-CLL) and plasma
cell myeloma (PCM) are mature B-cell neoplasms, and
their concomitancy in a patient, although rare, has been
previously reported [6-10]. Whether the same B-cell
originates both malignancies, in cases of concomitancy,
is a matter of controversy.* Correspondence: welbert.pereira@einstein.br
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reproduction in any medium, provided the orHere, we report a patient with a diagnosis of B-CLL
that developed concomitant PCM 6 years after leukemia
diagnosis. We characterized the two malignant popula-
tions by multi parametric flow cytometry and performed
cytogenetic analysis.Case presentation
A 60 year-old female patient was diagnosed with B-CLL
in 2005 with trisomy of the chromosome 12, revealed by
cytogenetic analysis. Plasma cell abnormalities were not
reported. The patient was treated with intermittent cycles
of chlorambucil and prednisone. On March 2011 the
patient developed anemia and thrombocytopenia and
on April 2011 she was seen at our institution for a
diagnostic workup.
There was no evidence of lymphadenopathy or hepa-
thosplenomegaly at the physical evaluation. Complete
blood counts revealed: hemoglobin: 8.6 g/dL; leucocytes:
1,300 cells/uL; neutrophils: 46.4%; lymphocytes: 38.6%;Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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aspiration, biopsy, cytogenetic analysis and immuno-
phenotyping were performed. It was observed 37.2% of
plasma cells and 6.8% of lymphocytes according to the
myelogram. Bone marrow cytogenetic analysis revealed
47, XX, +12 [9] /46,XX [11]. Bone marrow immunophe-
notyping revealed 25% of clonal plasma cells (CD38+;
CD56+; CD117+, IgG kappa+; CD19-; CD20-, CD45-;
lambda-) and 13% of abnormal B Lymphocytes (CD5+/
CD23+/CD19+/dim CD20+/CD38+/HLA-DR+/surface
IgM and IgD kappa+). Serum immunofixation revealed
IgG concentration of 3,990 mg/dL (normal range – 700
to 1,600 mg/dL). Serum protein electrophoresis uncovered
an IgG monoclonal peak. The patient was diagnosed
with concomitant CLL and IgG PCM. The patient was
treated with four cycles of rituximab, cyclophosphamide,
bortezomib and dexamethasone with partial improvement
of the cytopenias.
Another bone marrow study was done in June 2012.
Myelogram revealed 33.2% of lymphocytes and 18%
of plasma cells. Morphological analysis revealed small
lymphocytes presenting clumped chromatin and scant
cytoplasm, suggestive aspect of B-CLL. In addition, to
the high frequency of the plasma cells in the bone marrow,
some of them presented binucleated morphology, high
nucleus/cytoplasm ration, basophilic cytoplasma and
eccentric nucleus (Figure 1). Immunohistochemical ana-
lysis of bone marrow trephine biopsy showed infiltration
with plasma cells (20%) expressing CD138, kappa and
cyclin D1, and 10% of B-lymphocytes expressing CD5
and CD23. At that point, we decided to investigate the
clonal origin of B-CLL and PCM.
Using multi parametric flow cytometry, we found that
CD19(+) B-cells expressed CD5 (dim), CD20 (dim), CD23,
CD38, kappa light chain restriction, surface IgM and
IgD, and also were negative for CD10, CD22, FMC7
and lambda, compatible with a diagnosis of B-CLLA
Figure 1 Identification of B-CLL and abnormal plasma cell population
Rosenfeld’s staining and morphology analysis was performed in optical mic
the B-CLL and plasma cell myeloma populations.(Figure 2). Gating CD138 positive cells, we identified
the following pattern of expression on plasma cells:
CD38(+), CD56(+), cytoplasmatic kappa light chain(+),
cytoplasmatic IgG(+), and CD19(−), CD20(−), CD117(−),
CD33(−), HLA-DR(−), and CD45(−) (Figure 3). The
diagnosis of PCM was confirmed with clinical evaluation
and complementary exams (not shown). These data
confirmed the presence of concomitant B-CLL and PCM
in this patient.
Next, we investigated if a prior B-CLL clone could have
derived the PCM secondary disease. Since the patient
had a history of previous B-CLL with chromosome 12
trisomy, and this abnormality had already been reported,
albeit rarely, in PCM patients [11], we decided to study
whether the same cytogenetic abnormality was also
present in the PCM fraction. In order to isolate the
plasma cells, we performed a bone marrow magnetic
bead selection protocol using Human Whole Blood
CD138 Selection Kit (Easysep, Stem Cell Technologies),
obtaining CD138(+) and CD138(−) fractions. After that,
we analyzed the presence of chromosome 12 trisomy in
both samples by fluorescent in situ hybridization (FISH)
using the kit LSI ETV6(TEL)/RUNX1(AML1) ES DC
(Vysis, Inc). The analysis showed that 91% of the CD138
(−) cells were positive for chromosome 12 trisomy,
confirming the presence of this cytogenetic aberration
in B-CLL cells. However, all cells from the CD138(+)
fraction presented no additional copy of the chromosome
12 (Figure 4). Taken together, these observations suggest
that the PCM cells may not have derived from a B-CLL
clone, since the plasma cells did not carry the same
cytogenetic abnormality present in the CLL cells.
Conclusions
Concomitant B-CLL and PCM is rare, and the few pub-
lished cases are controversial regarding the clonal origin
of the two diseases. Considering that plasma cells mayCB
by morphology analysis. Bone marrow smears were dyed with
roscope. The panels A, B and C show the morphological aspects of
Figure 2 Characterization of the B-CLL population by flow cytometry immunophenotyping. A: The B cell population was gated by CD19
expression. B: Multiparametric dot plot showing T cell population (red), which is positive to CD5, and gated CD19+ B cells (blue), which
presented low but positive aberrant CD5. C: Multiparametric dot plot in bands showing the expression of a panel of markers in gated B cells
(blue dots). D: Multiparametric histograms confirming the monoclonality of the gated B cell population. Circles represent medians. Infinicyt Flow
Cytometry software (Cyotgnos, Salamanca, Spain) was used in the analysis.
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B-1 cells and also from memory B cells [12], it is pos-
sible that malignant plasma cells may have derived
from the B-CLL clone. Thus, in theory, under some still
unknown stimuli, a B cell from a patient with CLL
could differentiate into a plasma cell, generating a new
malignant disease.
The first publication of these concurrent neoplasias
described a B-CLL patient who developed a plamacytoma.
The authors suggested a common clonal origin based
only on the presence of the same heavy and light chains
in the two diseases [8]. One year later, Fermand and
colleagues investigated one case of B-CLL and PCM
producing IgG1 kappa and IgA kappa, respectively [7].
Using a more elegant approach, they cultured in vitro
the B-CLL cells and induced differentiation to plasma
cells, which in turn produced IgG and IgA. These data
allowed them to suggest that, under some circumstances,
PCM may be originated from B-CLL cells and conserve
the produced immunoglobulins. The theory of one clone
for these two concomitant diseases was strongly supported
by immunoglobulin gene rearrangement investigation.
Saltman and colleagues found the same rearrangements in
B cells from blood and bone marrow plasma cells, despite
different immunoglobulins isotypes [13]. One criticism tothis work is the possible cross contamination of the bone
marrow plasma cells with B cells from the blood, since
they performed no cell sorting approach.
On the other hand, distinct clonal origins for these
concomitant hematological neoplasias have been equally
proposed since 1985, based on the expressed immuno-
globulin chains [9] and later, based on the analysis of
B cell receptor rearrangement [14]. Patriarca and coworkers
reported a case of separate clonal evolution of PCM
(kappa light chain) after fludarabine treatment for the
B-CLL (lambda light chain), besides the two different
rearrangements of heavy chain immunoglobulin detected
in bone marrow, providing evidences of two clones [10].
Here, we described a case of B-CLL with chromosome 12
trisomy that developed concomitant PCM. We performed
a strict flow cytometry analysis to characterize the two
diseases, which revealed a B-CLL population expressing
IgM and IgD kappa on the surface of B cells, and the
PCM population expressing cytoplasmic IgG kappa.
Differential diagnosis, such as CLL with plasmacytic
differentiation and CD5+ lymphoplasmacytic lymphoma,
were excluded due to: i) the clear presence of two dis-
tinct malignant populations; ii) the absence of CD138
expression on CLL lymphocytes and the expression of
IgD on the surface of the CLL lymphocytes, unlikely
A B
C D
Figure 3 Characterization of the discrasic plasma cell population by flow cytometry immunophenotyping. A: The plasma cell population
was gated by CD138 expression. B: Multiparametric dot plot showing the aberrant expression of CD56 in all gated plasma cells. C: Multiparametric dot
plot in bands showing the expression of a panel of markers in gated plama cells (pink dots). D: Multiparametric dot plot in bands confirming the
monoclonality of the gated plasma cell population. Infinicyt Flow Cytometry software (Salamanca, Spain) was used in the analysis.
Figure 4 Identification of chromosome 12 trisomy in B-CLL cells, but not in myeloma cells by FISH. Dual color FISH for the genes ETV6
and RUNX1, whose probes detect the chromosome 12 (green) and chromosome 21 (red) respectively. A and B: Myeloma plasma cells presented
two copies of each chromosome, thus negative for the trisomy. C and D: Nucleus carrying chromosome 12 trisomy were detected in 91% the
cells in the CD138(−) fraction.
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of IgM paraprotein in the plasma of the patient [15].
The Chromosome 12 is considered as a marker of
poor prognosis in B-CLL patients [16], but it was never
correlated with myeloma development. Elnenaei and
collaborators [17] reported this cytogenetic alteration in
8% of their myeloma patients, but with no informative
data about previous hematological disorder, such as B-
CLL. We reported the absence of this alteration in
plasma cells, suggesting that PCM could have originated
independently, from a normal B-cell clone instead of a
malignant B-CLL one. We must consider the possibility
of PCM has been originated from a chromosome 12-
negative clone of B-CLL, or also from a chromosome
12-positive B-CLL clone with subsequent loss of the
additional chromosome. They are real possibilities, but
not well described in the literature.
Determination of the rearrangements in the immuno-
globulin genes is considered the gold standard to infer
clonal derivation in B cell neoplasm [18]. Nevertheless,
cytogenetic markers may also contribute to understand
the clonal relatedness and evolution in concurrent
malignant diseases [19]. Deletions, loss of heterozygosis,
duplications or translocations occur in several tumor
entities and become a molecular legacy in these cells.
Kaufmann and colleagues investigated cytogenetic markers
in lymphocytes and plasma cells of two patients with
concomitant B-CLL and myeloma, and likewise they
found no evidence of same clonality for these two diseases
[20]. Alternatively, it is clear that treatments for B-CLL
may induce transformation of other cells, generating a
new tumor entity [21], such as PCM, independently of
the B-CLL clones. This case report emphasizes the
importance of the close follow up of B-CLL patients
for early detection of other malignancies development,
such as plasma cell myeloma.
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